
|Videos|March 26, 2021
Dr. Swerdloff discusses the oral testosterone capsule Jatenzo
Author(s)Urology Times staff
Advertisement
Ronald S. Swerdloff, MD, MACP, discusses the approved indication and efficacy of Jatenzo (testosterone undecanoate), an oral testosterone capsule. Jatenzo is approved by the FDA as a testosterone replacement therapy for men with certain forms of hypogonadism. It is indicated for patients with low testosterone levels as a results of certain medical conditions, such as genetic disorders or cancer-related damage to their pituitary gland.
Swerdloff is a senior investigator at the Lundquist Institute, chief, Division of Endocrinology, Harbor-UCLA Medical Center, and professor of Medicine, David Geffen School of Medicine at UCLA.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
2
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
3
The Expert APProach: Advancing APP Leadership and Expertise in Urology, With Susanne Quallich, PhD, ANP-BC, NP-C
4
Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC
5










